News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inform Genomics Announces Results of Study Predicting Risk of Oral Mucositis in Patients Undergoing High Dose Chemotherapy


4/18/2012 10:40:25 AM

BOSTON--(BUSINESS WIRE)--Inform Genomics, Inc., a private company focused on developing novel platforms of personalized medicine products for cancer supportive care and inflammatory diseases, today announced the completion of the first phase of product development to predict a patient’s risk of developing oral mucositis after receiving high dose chemotherapy prior to hematopoietic stem cell transplant. The results of this single center, 153-patient study demonstrated the product’s ability to discriminate which patients develop oral mucositis with 99.3% accuracy and an area under the Receiver Operator Characteristic (ROC) curve of 99.7%. Further development will include validation of these initial results in a multicenter study. In addition, Inform Genomics announced that it entered into a collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) to further develop and commercialize the product. Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES